

Innovative medicines for cancer and other diseases using cell cycle & DNA damage response biology

Biotech Showcase - January 2017

Disclaimer

This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 about financial results and estimates, business strategy, clinical trial plans and research and development programs of Cyclacel Pharmaceuticals, Inc. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and current filings that have been filed with the Securities and Exchange Commission and are available at www.sec.gov. The information in this presentation is current as of this date. Cyclacel does not take any responsibility to update such information.

CYCLACEL

Cyclacel Highlights

Drugs against cancer based on cell cycle control biology

DNA damage modulation with sapacitabine oral capsules

- Ph 3 readout in front-line AML patients

DNA damage response with sapacitabine + seliciclib

- Oral combination: Ph 1 benefit in BRCA +ve patients

Transcriptional CDK2/9 inhibitor program

- Seliciclib (Ph 2) and CYC065 2nd gen CDK inhibitor (Ph 1)

Strong financial position & experienced management

- Est. capital through 2018 (beyond Ph 3 AML data readout)

Addressing large markets with limited competition

Source: Cyclacel press releases and data on file.

CYCLACEL

Translating Cancer Biology into Medicines

Profs David Lane (*p53*) **& David Glover** (*Polo & Aurora kinases*)

- Exploit cell cycle biology to disrupt cancer cell immortality:
  - *DNA DAMAGE RESPONSE Modulating cancer cell DNA repair*
  - *CELL CYCLE CONTROL Breaking cancer cell addiction to oncogenes*

Drug portfolio strategy

- Small molecules, enzyme targets (*DNA pol-α, CDK, PLK*)
- Phase 1 through Phase 3 trials completed
- Target profile: orally available, chronic treatments
- Low intensity treatment experience & patient QoL
- High value therapeutics

Source: Cyclacel data on file.

CYCLACEL

Pipeline

Program	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Marketed
Sapacitabine	AML	SEAMLESS Phase 3 registration study				
Sapacitabine	MDS	Phase 2 randomized study				
Sapacitabine + Seliciclib	Solid Tumors	Phase 1 BRCA +ve				
CYC065 CDK Inhibitor	Cancer	Phase 1 solid tumors				
CYC140 PLK Inhibitor	Cancer					
Investigator Sponsored Trials (IST)						
Seliciclib	Cushing's disease & Rheumatoid Arthritis					
Seliciclib	Cystic Fibrosis					

AML = acute myeloid leukemia. MDS = myelodysplastic syndromes. IND = investigational new drug.

CYCLACEL

The clinical problem of elderly AML

High Intensity iv Therapy +
Low Quality of Life + Old Age + Frailty
= High Mortality

CYCLACEL

Predicament of 70+ year old AML Patient

- Newly diagnosed: multigenetic, heterogeneous disease
- Old age, frailty and comorbidity

Options:

- 47-year old intensive iv chemotherapy regimen (“7+3”)
- Investigational clinical trial
- Hospice or terminal care at home



- Median survival of 3 - 6 months
- 60-day mortality of ~ 20 - 36%

CYCLACEL

MASSACHUSETTS GENERAL HOSPITAL

End of Life with AML: MGH 2007-2012



** Source: Foster J et al, Abstract 3318, ASH 2015.*

CYCLACEL

Our solution

Low Intensity Therapy +
Stay-at-Home Treatment =
Extended survival + High Quality of Life

CYCLACEL

SEAMLESS Phase 3 - *Low Intensity Strategy*

(Untreated AML: front line; ≥ 70 years; n=485; p=0.05; HR=0.725)



- ✓ In consultation with FDA under SPA
- ✓ Fully enrolled at 110 US & European hospitals

CYCLACEL

SEAMLESS Phase 3 Assumptions & Events *

≥27.5% reduction in risk of death

Median OS of:

- 8 months for experimental arm
- 6 months for control arm

Completed enrolment in December 2014

Required number of events reached

- Preparation for final analysis and reporting SEAMLESS outcomes underway

Anticipate reporting primary and secondary endpoints and submissibility to regulatory authorities in early 2017

** Source: Cyclacel data on file.*

CYCLACEL

SEAMLESS Pilot/Lead-in Study

Kaplan-Meier Survival Plot



No. at risk	3M	6M	12M	18M	24M
	38 (83%)	**30** (65%)	**16** (35%)	**12** (26%)	not reached

** Source: Ravandi F, et al, American Society of Hematology Annual Meeting Dec. 2012, Abstract #2630.*

K-M Plot, Pre-specified OS final Analysis

(DACO-016: Cut-off Oct. 28, 2009)



	N	Death	Median OS	95% CI
Dacogen	242	197 (81)	7.7	(6.2, 9.2)
TC	243	199 (82)	5.0	(4.3, 6.3)

No. of subjects at risk		6M	12M	18M	24M	30M	36M
Dacogen	242	137	65	28	12	1	0
TC	243	107	55	19	07	4	0

** Source: FDA Briefing Document, Dacogen ODAC, February 9, 2012. Of 242 treated with decitabine 39% were aged 75 years or older.*

CYCLACEL

Possible SEAMLESS Outcomes

Superior

Equivalent

Inferior

CYCLACEL

AML Market Opportunity Parameters

- US incidence: ~ 20,000; EU: ~ 22,000 patients
- Aged 70 years or older ~ 50% or 21,000 EU/US patients
- Assume 80% unfit/refuse intensive chemotherapy: available EU/US population of ~ 16,800 patients
- Indicative US annual cost of branded azacitidine or decitabine: ~$45,000-$65,000.

† Source: NCI SEER database, 2015 and Cyclacel proprietary market research.

CYCLACEL

Sapacitabine Competitive Positioning

- 1st line eAML: no approved drug since 1969
- Only orally-administered, low intensity drug
- Durability
- Well tolerated
- Convenience
- Line extensions (MDS, BRCA +ve cancers)
- Market research suggests ↑ unmet need

CYCLACEL

Cyclin Dependent Kinase Inhibitors:

Emerging novel oncology drug class

First CDK inhibitor approved in 2015 for breast cancer

Translating the 2001 Nobel Prize for Physiology & Medicine into treatments

Cyclacel's portfolio of CDK2/9 inhibitors:

- Seliciclib (Phase 2)
- CYC065 (Phase 1)

CYCLACEL

CDK Inhibitor Landscape *

CDK4/6 isoforms

- **palbociclib (PFE)** Approved in combination with letrozole for ER +ve Her2 -ve advanced BC
- **abemaciclib (LLY**; *also CDK9***)** Ph3
- **ribociclib (NVS)** Ph3

CDK2/9 "transcriptional" isoforms

- **seliciclib (CYCC)** Ph2
- **CYC065 (CYCC)** Ph1
- **dinaciclib (pan CDK, MRK)** Ph3
- **BAY1143572 (CDK9, BAY)** Ph1

** Source: Cyclacel data on file.*

CYCLACEL

Activity in HR-repair deficient tumors *

All-oral combo sapacitabine+seliciclib:

- durable clinical benefit (PRs & prolonged SD) in patients with BRCA +ve:
  - **breast,**
  - **ovarian,**
  - **pancreatic cancers**



…Opening new opportunities for line extensions…

** Source: Tolaney S et al, J Clin Oncol 34, 2016 (suppl; abstr 2503); Shapiro et al, AACR Proceedings, 2013, LB-202. HR=homologous recombination.*

Sapacitabine & Seliciclib Ph 1 Best Responses *

RECIST Evaluable BRCA Carriers

Cancer	Best Response	Prior Treatment	Total cycles
Part 1	*(n=16)*		
Breast	CR	adriamycin, cyclophosphamide, paclitaxel, cisplatin	>80
Breast	PR	adriamycin, cytoxan, paclitaxel, carboplatin	31
Ovary	SD	paclitaxel, carboplatin, gemcitabine	21
Ovary	PR	paclitaxel, carboplatin, gemcitabine, topotecan, iniparib	18
Breast	SD	tamoxifen, raloxifene, anastrozole, adriamycin, Cytoxan, paclitaxel, carboplatin, navelbine	7
Pancreas	PR	gemcitabine, 5-FU, oxaliplatin	7
Part 2	*(n=28)*		
Breast	PR	adriamycin, cytoxan, paclitaxel, capecitabine, irinotecan, ABT-888 (PARP inhibitor), MPDL3280A	>19
Ovary	SD	paclitaxel, carboplatin, doxil	22
Breast	SD	adriamycin, cytoxan, capecitabine, faslodex	12
Ovary	SD	paclitaxel, carboplatin, doxil, gemcitabine, topotecan, cytoxan, avastin	11
Ovary	SD	paclitaxel, carboplatin, doxil, olaparib (PARP inhibitor), cediranib	8
Ovary	SD	paclitaxel, carboplatin	4
Ovary	SD	paclitaxel, carboplatin, doxil, gemcitabine, alimta, cytoxan, avastin, olaparib (PARP inhibitor)	4
Pancreas	PR	gemcitabine, abraxane, docetaxel	4
Pancreas	SD	gemcitabine, cisplatin, abraxane, folfox, TH-302	4

ED AT: ASCO ANNUAL MEETING '16

Presented by: Sara M. Tolaney, MD, MPH

** Source: Tolaney S et al, J Clin Oncol 34, 2016 (suppl; abstr 2503).*

Sapacitabine & Seliciclib Phase 1 BRCA +ve Benefit*



** Source: Tolaney S et al, J Clin Oncol 34, 2016 (suppl; abstr 2503).*

Sapacitabine & Seliciclib Phase 1 BRCA +ve Benefit*



** Source: Tolaney S et al, J Clin Oncol 34, 2016 (suppl; abstr 2503).*

CYC065 CDK Inhibitor Overview

Intravenous or oral, potent & selective CDK2/9 inhibitor

Active in:

- Hematological malignancies (AML, MLL-r)
- BRCA /HRD +ve solid tumors; sapacitabine combination
- HER2 +ve solid tumors; trastuzumab combination

Therapeutic strategy: modulation of resistance

Significant market opportunity & unmet medical needs

Source: Cyclacel press releases and data on file.

CYCLACEL

Cancer Cells are Addicted to Oncogenes

Cancer propagated by:

- Inactivation of tumor suppressor genes (i.e. p27, p53);
- Activation of continuously expressed oncogenes required for cancer maintenance (i.e. KRAS, MYC):

➢ **ONCOGENE ADDICTION**

- Pharmacologic inhibition of oncogenes → **apoptosis or senescence & innate immune response** → cell death

Source: Weinstein I, Science 2002:297:63. Pelengaris S, et al, Cell 2002:109:321. Xue Lowe et al Nature 2007 doi:10.1038/nature05529. Cyclacel data on file.

CYCLACEL

CYC065 Activity in HER2^{+}, Cyclin E-addicted, Trastuzumab-resistant Breast Cancer



CYC065 single agent and in combination with trastuzumab *in vivo* tumor growth inhibition & regression (combination) of BT474R trastuzumab resistant HER2^{+} BC cell line.

Source: Scaltriti et al 2011 PNAS 108 3761

CYCLACEL

Financial Position & Capitalization

Pro Forma Cash & cash equivalents: $19.5m[1]

Operating cash burn (excludes non-cash items)

- ✓ 2013: ~ $18.2m annual [2]
- ✓ 2014: ~ $18.7m annual [2]
- ✓ 2015: ~ $14.5m annual [2]
- ✓ 2016: (est.) ~ $11.0m annual [3]

Fully diluted shares: ~ 4.6 million[4]

No debt

1. $18.0m, Sept. 2016 10-Q and $1.5m, ATM proceeds Oct. 2016 2. 10-K 3. Company estimate. 4. Sept. 2016 10-Q; common stock outstanding: 4.3m.

CYCLACEL

Key Catalysts

- Sapacitabine SEAMLESS: topline data readout and determination of submissibility
- Pre-submission regulatory consultations
- Sapacitabine & seliciclib solid tumors updated data
- Sapacitabine MDS combination after HMA failures
- CYC065 (CDK) First-in-Human Phase 1 study data

CYCLACEL

Investment Thesis

1st oral, low intensity Rx for elderly AML

Novel clinical & labeling strategy

Large market size + line extensions

Transcriptional CDKi oncology program with two promising clinical agents

Thank you for your support

ir@cyclacel.com



CYCLACEL